{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:11:17Z","timestamp":1789009877172,"version":"build-2803163510"},"reference-count":48,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2022.0149","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T11:06:07Z","timestamp":1648551967000},"source":"Crossref","is-referenced-by-count":3,"title":["Patients with multiple myeloma or monoclonal gammopathy of undetermined significance\u2014diagnosis, treatment, and follow-up"],"prefix":"10.3238","author":[{"given":"Vanessa","family":"Piechotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"10.3238\/arztebl.m2022.0149_ref1","doi-asserted-by":"crossref","unstructured":"Kazandjian D: Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 2016; 43: 676–81.","DOI":"10.1053\/j.seminoncol.2016.11.004"},{"key":"10.3238\/arztebl.m2022.0149_ref2","doi-asserted-by":"crossref","unstructured":"Cowan AJ, Allen C, Barac A, et al.: Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol 2018; 4: 1221–7.","DOI":"10.1001\/jamaoncol.2018.2128"},{"key":"10.3238\/arztebl.m2022.0149_ref3","unstructured":"RKI: Multiples Myelom. Krebs in Deutschland f\u00fcr 2017\/2018. Zentrum f\u00fcr Krebsregisterdaten und Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. Berlin 2021; 13: 138–41."},{"key":"10.3238\/arztebl.m2022.0149_ref4","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al.: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924–6.","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"10.3238\/arztebl.m2022.0149_ref5","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, AWMF): Diagnostik, Therapie und Nachsorge f\u00fcr Patienten mit monoklonaler Gammopathie unklarer Signifikanz (MGUS) oder Multiplem Myelom. 2022; Leitlinienreport 1.01, AWMF Registernummer: 018\/035OL. www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Multiples_Myelom\/LL_Multiples_Myelom_Leitlinienreport_1.0.pdf (last accessed on 23 February 2022)."},{"key":"10.3238\/arztebl.m2022.0149_ref6","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): Onkologische S3-Leitlinien – jetzt als App. 2021. www.leitlinienprogramm-onkologie.de\/app\/ (last accessed on 23 February 2022)."},{"key":"10.3238\/arztebl.m2022.0149_ref7","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): Onkologische Leitlinien. www.leitlinienprogramm-onkologie.de\/leitlinien\/ (last accessed on 23 February 2022)."},{"key":"10.3238\/arztebl.m2022.0149_ref8","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF): AWMF online. Das Portal der wissenschaftlichen Medizin. www.awmf.org\/awmf-online-das-portal-der-wissenschaftlichen-medizin\/ (last accessed on 19 January 2022)."},{"key":"10.3238\/arztebl.m2022.0149_ref9","unstructured":"McKenna RW, Kyle RA, Kuehl WM, Harris NL, Coupland RW, Fend F: Plasma cell neoplasms. In: WHO Classification of tumours of hematopoietic and lymphoid tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H (eds.). Lyon, IARC 2017: 241–53."},{"key":"10.3238\/arztebl.m2022.0149_ref10","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, Daviet A, Brigaudeau C, et al.: Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du My\u00e9lome and the Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique. Blood 2001; 97: 822–5.","DOI":"10.1182\/blood.V97.3.822"},{"key":"10.3238\/arztebl.m2022.0149_ref11","unstructured":"Dingli D, Ailawadhi S, Bergsagel PL, et al.: Therapy for relapsed multiple myeloma: guidelines from the mayo stratification for myeloma and risk-adapted therapy. Mayo Clin Proc 2017; 92: 578–98."},{"key":"10.3238\/arztebl.m2022.0149_ref12","doi-asserted-by":"crossref","unstructured":"Paquin AR, Kumar SK, Buadi FK, et al.: Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer J 2018; 8: 125.","DOI":"10.1038\/s41408-018-0163-7"},{"key":"10.3238\/arztebl.m2022.0149_ref13","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al.: International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538–48.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"10.3238\/arztebl.m2022.0149_ref14","doi-asserted-by":"crossref","unstructured":"Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S: The diagnosis and treatment of multiple myeloma. Dtsch Arztebl Int 2016; 113: 470–6.","DOI":"10.3238\/arztebl.2016.0470"},{"key":"10.3238\/arztebl.m2022.0149_ref15","unstructured":"W\u00f6rmann BDC, Einsele H, Goldschmidt H, et al.: Multiples Myelom. Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h\u00e4matologischer und onkologischer Erkrankungen. Berlin: DGHO Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie e. V.: 2018."},{"key":"10.3238\/arztebl.m2022.0149_ref16","doi-asserted-by":"crossref","unstructured":"Mikhael J, Ismaila N, Cheung MC, et al.: Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol 2019; 37: 1228–63.","DOI":"10.1200\/JCO.18.02096"},{"key":"10.3238\/arztebl.m2022.0149_ref17","doi-asserted-by":"crossref","unstructured":"Dhakal B, Szabo A, Chhabra S, et al.: Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol 2018; 4: 343–50.","DOI":"10.1001\/jamaoncol.2017.4600"},{"key":"10.3238\/arztebl.m2022.0149_ref18","doi-asserted-by":"crossref","unstructured":"Huang H, Zhou L, Peng L, Fu W, Zhang C, Hou J: Bortezomib–thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials. Leuk Res 2014; 38: 1048–54.","DOI":"10.1016\/j.leukres.2014.06.009"},{"key":"10.3238\/arztebl.m2022.0149_ref19","unstructured":"Moreau P, Attal M, Hulin C, et al.: Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019; 394: 29–38."},{"key":"10.3238\/arztebl.m2022.0149_ref20","doi-asserted-by":"crossref","unstructured":"Munshi NC, Avet-Loiseau H, Rawstron AC, et al.: Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol 2017;3: 28–35.","DOI":"10.1001\/jamaoncol.2016.3160"},{"key":"10.3238\/arztebl.m2022.0149_ref21","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al.: Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32: 309–22.","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"10.3238\/arztebl.m2022.0149_ref22","unstructured":"Moreau P, Kumar SK, San Miguel J, et al.: Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol 2021; 22: e105-18."},{"key":"10.3238\/arztebl.m2022.0149_ref23","doi-asserted-by":"crossref","unstructured":"Goyal G, Bartley AC, Funni S, et al.: Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. Leukemia 2018; 32: 1414–20.","DOI":"10.1038\/s41375-018-0099-8"},{"key":"10.3238\/arztebl.m2022.0149_ref24","unstructured":"Onkologie L: Erweiterte S3-Leitlinie Palliativmedizin f\u00fcr Patienten mit einer nicht-heilbaren Krebserkrankung 2020."},{"key":"10.3238\/arztebl.m2022.0149_ref25","doi-asserted-by":"crossref","unstructured":"Knips L, Bergenthal N, Streckmann F, Monsef I, Elter T, Skoetz N: Aerobic physical exercise for adult patients with haematological malignancies. Cochrane Database Syst Rev 2019; 1: CD009075.","DOI":"10.1002\/14651858.CD009075.pub3"},{"key":"10.3238\/arztebl.m2022.0149_ref26","doi-asserted-by":"crossref","unstructured":"Barthels FR, Smith NS, S\u00f8nderskov G\u00f8rl\u00f8v J, et al.: Optimized patient-trajectory for patients undergoing treatment with high-dose chemotherapy and autologous stem cell transplantation. Acta Oncol 2015; 54: 750–8.","DOI":"10.3109\/0284186X.2014.999872"},{"key":"10.3238\/arztebl.m2022.0149_ref27","doi-asserted-by":"crossref","unstructured":"Hacker ED, Larson J, Kujath A, Peace D, Rondelli D, Gaston L: Strength training following hematopoietic stem cell transplantation. Cancer Nurs 2011; 34: 238–49.","DOI":"10.1097\/NCC.0b013e3181fb3686"},{"key":"10.3238\/arztebl.m2022.0149_ref28","doi-asserted-by":"crossref","unstructured":"Oechsle K, Aslan Z, Suesse Y, Jensen W, Bokemeyer C, de Wit M: Multimodal exercise training during myeloablative chemotherapy: a prospective randomized pilot trial. Support Care Cancer 2014; 22: 63–9.","DOI":"10.1007\/s00520-013-1927-z"},{"key":"10.3238\/arztebl.m2022.0149_ref29","doi-asserted-by":"crossref","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, et al.: Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018; 378: 518–28.","DOI":"10.1056\/NEJMoa1714678"},{"key":"10.3238\/arztebl.m2022.0149_ref30","doi-asserted-by":"crossref","unstructured":"Mateos MV, Cavo M, Blade J, et al.: Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 2020; 395: 132–41.","DOI":"10.1016\/S0140-6736(19)32956-3"},{"key":"10.3238\/arztebl.m2022.0149_ref31","doi-asserted-by":"crossref","unstructured":"Facon T, Kumar S, Plesner T, et al.: Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019; 380: 2104–15.","DOI":"10.1056\/NEJMoa1817249"},{"key":"10.3238\/arztebl.m2022.0149_ref32","doi-asserted-by":"crossref","unstructured":"Facon T, Kumar SK, Plesner T, et al.: Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 1582–96.","DOI":"10.1016\/S1470-2045(21)00466-6"},{"key":"10.3238\/arztebl.m2022.0149_ref33","doi-asserted-by":"crossref","unstructured":"Durie BGM, Hoering A, Abidi MH, et al.: Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017; 389: 519–27.","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"10.3238\/arztebl.m2022.0149_ref34","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, et al.: Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22: 801–12."},{"key":"10.3238\/arztebl.m2022.0149_ref35","doi-asserted-by":"crossref","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H, et al.: Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 2018; 36: 728–34.","DOI":"10.1200\/JCO.2017.76.5032"},{"key":"10.3238\/arztebl.m2022.0149_ref36","doi-asserted-by":"crossref","unstructured":"Grosicki S, Simonova M, Spicka I, et al.: Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 2020; 396: 1563–73.","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"10.3238\/arztebl.m2022.0149_ref37","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Quach H, Mateos M-V, et al.: Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol 2022; 23: 65–76.","DOI":"10.1016\/S1470-2045(21)00579-9"},{"key":"10.3238\/arztebl.m2022.0149_ref38","doi-asserted-by":"crossref","unstructured":"Spencer A, Lentzsch S, Weisel K, et al.: Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica 2018; 103: 2079–87.","DOI":"10.3324\/haematol.2018.194118"},{"key":"10.3238\/arztebl.m2022.0149_ref39","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Lonial S, Betts KA, et al.: Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer 2018; 124: 4032–43.","DOI":"10.1002\/cncr.31680"},{"key":"10.3238\/arztebl.m2022.0149_ref40","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, et al.: Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018; 379: 1811–22.","DOI":"10.1056\/NEJMoa1805762"},{"key":"10.3238\/arztebl.m2022.0149_ref41","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, et al.: Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17: 27–38."},{"key":"10.3238\/arztebl.m2022.0149_ref42","doi-asserted-by":"crossref","unstructured":"Orlowski RZ, Moreau P, Niesvizky R, et al.: Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups. Clin Lymphoma Myeloma Leuk 2019; 19: 522–30.e1.","DOI":"10.1016\/j.clml.2019.04.018"},{"key":"10.3238\/arztebl.m2022.0149_ref43","doi-asserted-by":"crossref","unstructured":"Attal M, Richardson PG, Rajkumar SV, et al.: Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019; 394: 2096–107.","DOI":"10.1097\/01.HS9.0000561576.58696.ae"},{"key":"10.3238\/arztebl.m2022.0149_ref44","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, et al.: Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 2021; 397: 2361–71."},{"key":"10.3238\/arztebl.m2022.0149_ref45","unstructured":"Richardson PG, Oriol A, Beksac M, et al.: Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 781–94."},{"key":"10.3238\/arztebl.m2022.0149_ref46","doi-asserted-by":"crossref","unstructured":"Bahlis NJ, Dimopoulos MA, White DJ, et al.: Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 2020; 34: 1875–84.","DOI":"10.1038\/s41375-020-0711-6"},{"key":"10.3238\/arztebl.m2022.0149_ref47","doi-asserted-by":"crossref","unstructured":"Moreau P, Masszi T, Grzasko N, et al.: Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 374: 1621–34.","DOI":"10.1056\/NEJMoa1516282"},{"key":"10.3238\/arztebl.m2022.0149_ref48","doi-asserted-by":"crossref","unstructured":"Richardson PG, Kumar SK, Masszi T, et al.: Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 2021; 39: 2430–42.","DOI":"10.1200\/JCO.21.00972"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T11:07:23Z","timestamp":1648552043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":48,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2022.0149","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]}}}